Skip to main content
. 2015 Feb 20;11(2):355–372. doi: 10.4161/15548627.2014.994368

Figure 5.

Figure 5.

Vismodegib inhibited the AKT-MTOR signaling pathway in CML cells. (A) K562 cells were treated with 10, 20, and 40 μM of vismodegib (Vis) for 48 h, the protein levels of p-AKT (Ser473), p-AKT (Thr308), p-MTOR (Ser2448), p-RPS6KB1 (Thr389), p-EIF4EBP1 (Thr37/46), SQSTM1, MAP1LC3B, and ACTB were measured by western blot assays. (B) Densitometric values were quantified using the ImageJ software and normalized to control. The values of control were set to 1. The data are presented as means ± SD of 3 independent experiments. (C) K562 cells were treated with or without 20 μM of vismodegib for 12 h, 24 h, and 48 h, the protein levels of p-AKT (Ser473), p-AKT (Thr308), p-MTOR (Ser2448), p-RPS6KB1 (Thr389), p-EIF4EBP1 (Thr37/46), SQSTM1, MAP1LC3B, and ACTB were measured by western blot assays. (D) Densitometric values were quantified as described in (B).